Decode Buys Cancer Research Firm UVS for $5.5M in Stock

genomeweb
360dx

Decode Buys Cancer Research Firm UVS for $5.5M in Stock

Jan 18, 2006

NEW YORK, Jan. 18 (GenomeWeb News) - Decode Genetics has bought Urdur, Verdandi, Skuld, a privately held Icelandic cancer research company, to expand its discovery and drug development capabilities based on population genetics, Decode said today.

To read the full story....

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

UgenTec, Serosep Partner on Molecular Test Automation, Interpretation
Mobidiag Gets CE Mark for Two Tests
BioMérieux Q1 Revenues Up 3 Percent
Danaher Q1 Revenues Grow 12 Percent
FDA Expands Approval of Roche Cobas Test as CDx for EGFR Deletions, Mutations
Curetis Gets CE Mark for UTI Test

The Scan

Drive Away the Flies

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

Fewer Transfusions Needed

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

This Week in Nature

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Alteration Here and There to Win

Futurism writes that gene doping could be the next generation of cheating in sports.

Main menu